A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors

Cancer Research

Volumn 61, Issue 14, 2001, Pages 5480-5485

  Tahir, Stephen K ^a   Han, Edward K H ^a   Credo, Bruce ^a   Jae, Hwan Soo ^a   Pietenpol, Jennifer A ^c   Scatena, Caroline D ^c   Wu Wong, Jinshyun R ^b   Frost, David ^a   Sham, Hing ^a   Rosenberg, Saul H ^a   Ng, Shi Chung ^a  

^a ABBOTT LABORATORIES   (United States)

^b ABBOTT DIAGNOSTICS   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 ACETYL 4,5 DIHYDRO 5 (3,4,5 TRIMETHOXYPHENYL) 1,3,4 OXADIAZOL 2 YL] N,N DIMETHYLBENZENEAMINE; COLCHICINE; GLYCOPROTEIN P; OXADIAZOLE DERIVATIVE; PACLITAXEL; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DEPOLYMERIZATION; DOSE RESPONSE; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MEMBRANE TRANSPORT; MICROTUBULE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; COLCHICINE; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; G2 PHASE; HUMANS; MICROTUBULES; MITOSIS; OXADIAZOLES; PACLITAXEL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; TUBULIN; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0035879010     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Cytoskeletal organization following cannabinoid treatment in undifferentiated and differentiated PC12 cells
2. Cannabinoid enantiomer action on the cytoarchitecture
3. Antimitotic natural products and their interactions with tubulin
4. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle
5. Antimicrotubule agents
6. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents
7. Antimitotic agents
8. Raf-1/bcl12 phosphorylation: A step from microtubule damage to cell death
9. Clinical multidrug resistance in cancer: A multifactorial problem
10. P-glycoprotein-a mediator of multidrug resistance in tumour cells
11. Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells
12. Modulation of drug resistance by α-tubulin in paclitaxel-resistant human lung cancer cell lines
13. Activation of the CED3/ICE-related protease CPP32 in cerebellar granule meurons undergoing apoptosis but not necrosis
14. Microtubule assembly in the absence of added nucleotides
15. A rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin
16. 50) of an enzymatic reaction
17. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and taxol-induced growth arrest
18. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute anticancer drug screen
19. Modulation of taxol resistance by annexin IV in lung cancer cells
20. Coupling cell division and cell death to microtubule dynamics
21. Possible mechanisms of paclitaxel-induced apoptosis
22. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitoite exit and apoptotic cell death
23. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway
24. Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage
25. Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein
26. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells